triazoles has been researched along with baricitinib in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 11 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y | 1 |
| Westhovens, R | 1 |
| Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Lee, YH; Song, GG | 2 |
| Georgiou, S; Plachouri, KM | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Singh, S | 1 |
| Lee, YH; Sung, YK | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Adas, M; Bechman, K; Cope, AP; Galloway, JB; Mootoo, A; Norton, S; Patel, V; Qureshi, S; Rampes, S; Yates, M | 1 |
| Campigotto, F; Di Paolo, JA; Galien, R; Meng, A; Murray, B; Traves, PG | 1 |
| Fearon, U; Flynn, K; Hanlon, MM; Marzaioli, V; O'Brien, A; Veale, DJ; Wade, SC | 1 |
10 review(s) available for triazoles and baricitinib
| Article | Year |
|---|---|
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2016 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Cytokines; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Triazoles | 2020 |
Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pulmonary Embolism; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles; Venous Thromboembolism; Venous Thrombosis | 2021 |
4 other study(ies) available for triazoles and baricitinib
| Article | Year |
|---|---|
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles | 2019 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Triazoles | 2021 |
Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
Topics: Adamantane; Adult; Aged; Arthritis, Psoriatic; Azetidines; Cells, Cultured; Female; Fibroblasts; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Niacinamide; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Synovial Membrane; Triazoles | 2021 |